MX9304075A - Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos. - Google Patents

Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.

Info

Publication number
MX9304075A
MX9304075A MX9304075A MX9304075A MX9304075A MX 9304075 A MX9304075 A MX 9304075A MX 9304075 A MX9304075 A MX 9304075A MX 9304075 A MX9304075 A MX 9304075A MX 9304075 A MX9304075 A MX 9304075A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
pct
disorders
pharmaceutical composition
Prior art date
Application number
MX9304075A
Other languages
English (en)
Inventor
Arnaud Ythier
Jean-Claude Mestries
Francis Herodin
Serge Martin
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929214489A external-priority patent/GB9214489D0/en
Priority claimed from GB939301251A external-priority patent/GB9301251D0/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MX9304075A publication Critical patent/MX9304075A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona el uso de una interleucina-6 en la manufactura de un medicamento para el tratamiento o profilaxis de un desorden tromohemorrágico consuntivo. La invención también proporciona el uso de la interleucina-6 en al manufactura de un medicamento para el tratamiento o profilaxis de un a disfunción asociada con un nivel reducido de al menos una proteína de la fase aguda.
MX9304075A 1992-07-08 1993-07-07 Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos. MX9304075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929214489A GB9214489D0 (en) 1992-07-08 1992-07-08 Pharmaceutical compositions and uses therefor
GB939301251A GB9301251D0 (en) 1993-01-22 1993-01-22 Pharmaceutical compositions and use therefor

Publications (1)

Publication Number Publication Date
MX9304075A true MX9304075A (es) 1994-04-29

Family

ID=26301225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304075A MX9304075A (es) 1992-07-08 1993-07-07 Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.

Country Status (13)

Country Link
US (1) US5925344A (es)
EP (1) EP0651648B1 (es)
JP (1) JP3845112B2 (es)
AT (1) ATE228848T1 (es)
AU (1) AU674864B2 (es)
CA (1) CA2139353C (es)
DE (1) DE69332541T2 (es)
DK (1) DK0651648T3 (es)
ES (1) ES2183814T3 (es)
IL (1) IL106272A (es)
MX (1) MX9304075A (es)
PT (1) PT651648E (es)
WO (1) WO1994001123A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
CN1434703A (zh) * 2000-08-24 2003-08-06 利统股份有限公司 延迟释放组合物及组合
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
BR112012008970A2 (pt) * 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2477530C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к интерлейкину-6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
JPH0372429A (ja) * 1988-10-07 1991-03-27 Chugai Pharmaceut Co Ltd 血小板減少症の治療剤
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5188828A (en) * 1990-11-08 1993-02-23 Brigham And Women's Hospital Interleukin-6 to stimulate erythropoietin production
AU9059991A (en) * 1990-11-13 1992-06-11 Children's Medical Center Corporation Controlling beta-amyloid related neuronal degeneration by antagonizing NGF-effected neuronal activity
WO1993006840A1 (fr) * 1991-10-09 1993-04-15 Toray Industries, Inc. Medicament de prevention et de traitement de la tendance a l'hemorragie

Also Published As

Publication number Publication date
AU4566493A (en) 1994-01-31
CA2139353C (en) 2006-11-07
JP3845112B2 (ja) 2006-11-15
DK0651648T3 (da) 2003-01-06
EP0651648A1 (en) 1995-05-10
AU674864B2 (en) 1997-01-16
PT651648E (pt) 2003-04-30
CA2139353A1 (en) 1994-01-20
JPH08502028A (ja) 1996-03-05
WO1994001123A1 (en) 1994-01-20
IL106272A0 (en) 1993-11-15
EP0651648B1 (en) 2002-12-04
DE69332541D1 (de) 2003-01-16
ATE228848T1 (de) 2002-12-15
ES2183814T3 (es) 2003-04-01
IL106272A (en) 1999-01-26
DE69332541T2 (de) 2003-04-17
US5925344A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
ES2113635T3 (es) Aplicacion del riluzole en el tratamiento de lesiones neurologicas relacionadas con traumatismos.
DK0589893T3 (da) Anvendelse af et bakteriocin som antimikrobielt middel til fremstilling af et lægemiddel til behandl ing af maveforstyrrelser forbundet med helicobacter pylori
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
PT95760A (pt) Metodo para o tratamento de perturbacoes relacionadas com a ansiedade usando sertralina
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
DE69232516D1 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ES2094638T3 (es) N-acilpirrolidinas y medicamentos para el tratamiento o la prevencion de los desordenes relacionados con la colecistoquinina y la gastrina.
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
PT720483E (pt) Utilizacao de hormona de crescimento no fabrico de um medicamento para o tratamento de lesao cerebral isquemica e demencia
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
ES2158089T3 (es) Uso de derivados de fosforo de alcaloides para el tratamiento de endocrinopatias.
DK0691846T3 (da) Imidazoquinoxalinoner til behandling af sygdomme i centralnervesystemet
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees